BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?

Imatinib, the first-in-class BCR-ABL tyrosine kinase inhibitor (TKI), had been a revolution for the treatment of chronic myeloid leukemia (CML) and had greatly enhanced patient survival. Second- (dasatinib, nilotinib, and bosutinib) and third-generation (ponatinib) TKIs have been developed to be eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Haguet, Hélène, Douxfils, Jonathan, Chatelain, Christian, Graux, Carlos, Mullier, François, Dogné, Jean-Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524858/
https://www.ncbi.nlm.nih.gov/pubmed/31249931
http://dx.doi.org/10.1055/s-0038-1624566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524858/
https://www.ncbi.nlm.nih.gov/pubmed/31249931
http://dx.doi.org/10.1055/s-0038-1624566

Ejemplares similares